BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Avid Bioservices, Inc. Announces Addition of Novel Bacteriophage Production System at Upcoming Biotechnology Industry Organization (BIO) Conference as Part of a Collaboration With Phage Pharmaceuticals (Formerly Known as Phage Biotechnology Corp.)


6/12/2012 8:36:34 AM

TUSTIN, CA--(Marketwire - June 11, 2012) - Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that it will collaborate with San Diego-based Phage Pharmaceuticals, whereby Avid will add a custom protein production service using Phage's novel bacteriophage production system to its suite of current client offerings. This new service will be formally launched at the upcoming Biotechnology Industry Organization (BIO) International Convention from June 18-21, 2012 in Boston, Massachusetts. Further details on the partnership were not disclosed.

"By partnering with Phage, we complement our existing services portfolio with Phage's facility, which is dedicated to microbial production, and we believe this strategic addition will benefit our clients' projects by enhancing protein production, to yield more stable and potent proteins," said Steven W. King, president of Avid Bioservices. "We are pleased to be working with Phage to offer their proprietary expression system, as it has many advantages and serves as an extension of our existing cGMP protein production services."

"Avid's established reputation in the industry as a supplier of broad biomanufacturing capabilities, supporting production at every stage of development, makes them an ideal partner for us," said Jamie Oliver, Pharm.D., president & chief executive officer at Phage Pharmaceuticals. "Phage's manufacturing process improves upon well-established approaches for the manufacture of targeted proteins and results in production of properly folded, soluble therapeutic proteins, at high yields. We believe this will be a great asset to Avid's already comprehensive list of service offerings."

About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.

About Phage Pharmaceuticals
Phage Pharmaceuticals is a private San Diego, California-based clinical-stage specialty biopharmaceutical company that develops and manufactures therapeutic proteins using a proprietary production method at its own government-certified cGMP facility. The company develops therapeutic proteins for niche markets and indications for which there already exists evidence of safety and efficacy in humans. Additional information about Phage can be found at www.phagepharma.com.


Contact:
Chris Keenan or Kelly Lord
(800) 987-8256
www.avidbio.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES